Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 28, 2012

View Archived Issues

Resiniferatoxin improves urodynamic parameters in patients with overactive bladder

Solabegron demonstrates efficacy in phase II study

Long-term and post hoc phase III data presented on mirabegron

Ventana Medical Systems image analysis application cleared for use in U.S.

MorphoSys announces signing of protein engineering agreement

Affymax to receive milestone payment related to peginesatide

Watson Pharmaceuticals receives FDA complete response letter for vaginal gel

Ready-to-use oral therapy approved in China for oral mucositis in patients with cancer

Stem CentRx reports new APCDD1-binding antibodies

Bayer Schering Pharma patents novel potential anticancer agents

Novel antibacterials announced by Ranbaxy Laboratories

New aryl hydrocarbon receptor modulators developed in U.S.

New recombinant bacteria designed in Canada

Novartis identifies novel acetyl-CoA carboxylase 2 inhibitors

Study shows predictive value of PET/CT findings in retinoblastoma

Merck & Co. licenses Protein Sciences technology for vaccine research

Biodesix enters new collaboration

Advaxis reports data from first cohort in phase II ADXS-HPV trial

FDA grants priority review to Xarelto sNDA

Tranzyme Pharma and Norgine give update on ULISES 008 study

Two phase III cariprazine studies in schizophrenia meet primary endpoint

FDA grants fast track status to epicutaneous skin patch for peanut allergy

Apeiron begins study in prevention of radiation dermatitis

FDA grants Repros meeting to discuss Androxal development

Adocia's fast-acting human insulin comparable to NovoLog in phase IIa trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...